Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / HALO - J&J's Janssen division wins European approval of Darzalex subcutaneous formulation

HALO - J&J's Janssen division wins European approval of Darzalex subcutaneous formulation

Halozyme Therapeutics Inc.
Michael Vi/iStock Editorial via Getty Images Johnson & Johnson's (JNJ) Janssen division received two European Commission ("EC") marketing authorizations for Darzalex SC, a subcutaneous formulation of Darzalex (daratumumab). The first is for Darzalex SC in combination with Velcade (bortezomib), cyclophosphamide, and dexamethasone for the  newly diagnosed systemic light-chain amyloidosis. The second is for Darzalex SC in combination with Pomalyst (pomalidomide) and dexamethasone as a second- or third-line therapy for multiple myeloma. In August 2012, Genmab (GMAB) granted Janssen an exclusive worldwide license to develop, manufacture and commercialize Darzalex. Darzalex SC is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), a drug delivery technology from Halozyme (HALO). J&J shares are down 7 cents to $163.77 in afternoon trading.

For further details see:

J&J's Janssen division wins European approval of Darzalex subcutaneous formulation
Stock Information
Company Name: Halozyme Therapeutics Inc.
Stock Symbol: HALO
Market: NASDAQ
Website: halozyme.com
Menu
HALO HALO Quote HALO Short HALO News HALO Articles HALO Message Board
Get HALO Alerts

News, Short Squeeze, Breakout and More Instantly...